Aventis Pharma Deutschland, Gmbh

Sanofi-A Ventis Deutschland Gmbh

Wacker-Chemie Gmbh

Johann Ertl

Paul Habermann

Gerhard Seipke

Karl Geisen

Johannes Meiwes

Axel Wollmer

Gerald Preibisch

G&uuml;nter M&uuml;ller

Fusion protein including a fusion part and a protein of interest, the combination of the two proteins leading to the fusion protein being secreted into a supernatant of a bacterial host with the protein of interest being present in its correct three-dimensional structure. Nucleic acid including a sequence coding for a fusion protein, the sequence including: &#x2014;F&#x2014;As&#x2014;R&#x2014;Y&#x2014;, where F is a nucleic acid sequence coding for an amino acid sequence which allows secretion of a protein encoded by Y into a fermentation medium, As is a chemical bond or a nucleic acid sequence comprising a codon, m is an integer from 0&#x2013;10, R is a chemical bond or an arginine codon, n is 0 or 1, and Y is a nucleic acid sequence coding for a protein of interest. Processes therefor.

Fusion proteins capable of being secreted into a fermentation medium

The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.

Insulin analogs with enhanced zinc binding

C peptide for improved preparation of insulin and insulin analogs

The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

Use of leptin antagonists for treating insulin resistance in type II diabetes

The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.

Insulin derivatives having a rapid onset of action

Insulin derivatives with increased zinc binding

Growing community of inventors

Eppstein, Germany

Johann Ertl